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Abstract
The sodium-glucose-cotransporter-2 (SGLT2) inhibitor dapagliflozin (DAPA) induces gluco-
suria and osmotic diuresis via inhibition of renal glucose reabsorption. Since increased di-
uresis retards the progression of polycystic kidney disease (PKD), we investigated the
effect of DAPA in the PCK rat model of PKD. DAPA (10 mg/kg/d) or vehicle was adminis-
tered by gavage to 6 week old male PCK rats (n=9 per group). Renal function, albuminuria,
kidney weight and cyst volume were assessed after 6 weeks of treatment. Treatment with
DAPA markedly increased glucose excretion (23.6 ± 4.3 vs 0.3 ± 0.1 mmol/d) and urine out-
put (57.3 ± 6.8 vs 19.3 ± 0.8 ml/d). DAPA-treated PCK rats had higher clearances for creati-
nine (3.1 ± 0.1 vs 2.6 ± 0.2 ml/min) and BUN (1.7 ± 0.1 vs 1.2 ± 0.1 ml/min) after 3 weeks,
and developed a 4-fold increase in albuminuria. Ultrasound imaging and histological analy-
sis revealed a higher cyst volume and a 23% higher total kidney weight after 6 weeks of
DAPA treatment. At week 6 the renal cAMP content was similar between DAPA and vehicle,
and staining for Ki67 did not reveal an increase in cell proliferation. In conclusion, the inhibi-
tion of glucose reabsorption with the SGLT2-specific inhibitor DAPA caused osmotic diure-
sis, hyperfiltration, albuminuria and an increase in cyst volume in PCK rats. The
mechanisms which link glucosuria to hyperfiltration, albuminuria and enhanced cyst volume
in PCK rats remain to be elucidated.
Introduction
Polycystic kidney diseases (PKD) are the most frequent entities among the genetically deter-
mined renal syndromes [1]. The autosomal dominant form of PKD (ADPKD) is twenty times
more frequent than the autosomal recessive form (ARPKD) [2]. Approximately 5–8% of all pa-
tients with end-stage renal disease (ESRD) suffer from ADPKD [3]. Although progress has re-
cently been made in the development of treatments which retard the cystic growth, no therapy
was shown to be effective in delaying the occurrence of ESRD [4].
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It has been shown that renal cAMP is a major driver of cyst growth in PKD [5]. The exces-
sive cAMP production is a consequence of the genetic defect which underlies PKD [6]. Due to
an early loss of the urine concentrating capability the production of vasopressin is upregulated
in PKD, stimulating the production of cAMP directly through its V2 receptor in the distal renal
epithelium [7]. Therapeutic strategies which decrease the vasopressin-driven cAMP produc-
tion have been successful in decreasing renal cyst growth and in slowing the decline of renal
function in PKD [8–11]. Thus, treatment of mice, rats and humans with the vasopressin V2-re-
ceptor antagonist tolvaptan [12], crossing PKD rats (PCK strain) with vasopressin-deficient
rats (Brattleboro strain) [13], or increasing fluid intake in rats by adding glucose to the drinking
water [14] have all been effective to retard PKD disease progression. Patients with ADPKD
tend to have a higher urine output because of a renal concentrating defect and a blunted release
of vasopressin [15], but presumably also because drinking large amounts of water has been rec-
ommended to patients with ADPKD in an attempt to reduce cyst growth [16,17].
As mentioned, the aquaretic drug tolvaptan (vasopressin V2 receptor antagonist) was
shown to have beneficial effects on polycystic kidney disease progression. It is not known
whether the induction of osmotic diuresis would also have such a beneficial effect. We have
previously shown that the induction of osmotic diuresis by inhibiting renal proximal tubular
sodium-glucose cotransport (SGLT) with phlorizin retards cyst growth and renal functional
decline in the Han:SPRD rat model of PKD [18]. Phlorizin is a nonselective SGLT inhibitor
which inhibits SGLT1 and SGLT2. In recent years, selective SGLT2 inhibitors have been devel-
oped and are now in clinical use for the treatment of hyperglycemia in patients with type 2 dia-
betes mellitus [19]. To evaluate whether the selective inhibition of SGLT2 is capable of
retarding cyst volume progression and delaying renal functional loss, we tested the effect of
oral dapagliflozin (DAPA) administration in PCK rats, an orthologous model of ARPKD.
Materials and Methods
Ethics statement
All animal work was conducted according to relevant national and international guidelines.
The protocol was approved by the committee on the Ethics of Animal Experiments at the Uni-
versity of Zürich (Permit Number: 175–2012). All efforts were made to minimize any suffering
to animals.
Animals
PCK rats (an orthologous model of autosomal recessive polycystic kidney disease) and normal
Sprague-Dawley (SD) rats were used in this study. PCK rats (originally derived from SD rats)
were obtained from Charles River Laboratories (Sulzfeld, Germany) while SD rats were ob-
tained from the Rat Resource and Research Center (Columbia, MO, USA). All rats had free ac-
cess to tap water and were fed a standard rat diet. Only male rats were used in this study as
cysts develop more rapidly in male compared with female rats.
Experimental design
DAPA (Bristol-Myers Squibb, Princeton, New Jersey) was dissolved in a vehicle of polypropyl-
ene glycol, water and ethanol (45:45:10, v/v/v). At 5–6 weeks of age, male PCK or normal con-
trol SD rats (n = 8–9 per group) were given DAPA (10 mg/kg/d) or vehicle by gavage for 5–6
weeks. The doses of the drug and the vehicle were adjusted daily according to the body weight
of the rats. Blood was drawn and 24 h urine was collected at baseline and after 2–3 and 5–6
weeks of treatment to assess different parameters of renal function. At the end of the treatment
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phase (at 12 week of age), the PCK rats were examined by ultrasound to determine the kidney
and cyst volume in vivo. All rats were then sacrificed and the kidneys were excised, decapsu-
lated and weighed to calculate the two kidneys to total body weight (2K/TBW) ratios. Kidney
slices were fixed in 10% buffered formalin and were then embedded in paraffin for subsequent
histological examinations.
Plasma and urine analyses
Plasma and urine aliquots were rapidly frozen and stored at -80°C until their measurement.
Glucose, sodium, chloride, creatinine and blood urea nitrogen (BUN) concentrations were de-
termined in plasma and urine using a Cobas 8000 Modular Analyzer from Roche Diagnostics
AG (Rotkreuz, Switzerland). Plasma and urine osmolality were measured by using an Ad-
vanced Osmometer Model 2020 (Advanced Instruments Inc., Norwood, MA, USA). The urine
protein content was analyzed by SDS-PAGE and Coomassie blue staining, adjusting the load-
ing volumes of the samples to the 24 h urine volume. The GenWay rat albumin ELISA kit (San
Diego, CA, USA) was used to measure urine albumin concentration, according to the instruc-
tions provided by the manufacturer.
Ultrasound imaging of rat kidneys
PCK rats were anesthetized with isoflurane (1.5–2%) in oxygen. Physiological variables (heart
rate, respiratory rate, rectal temperature) were continuously monitored by using a VisualSonics
Advanced Physiological Monitoring Unit (Toronto, Ontario, Canada). The abdomen was
clipped and all hair was removed using Veet hair removal cream. Acoustic coupling was en-
sured using ultrasound coupling gel. Ultrasound images of the kidneys were acquired using a
high resolution ultrasound system (Vevo 2100, VisualSonics) equipped with a 18–38 MHz
probe (MS400). Following image optimization, transverse 2D and power Doppler images of
both kidneys were acquired with the aid of an automated 3D motor head. Care was taken to
include the cranial and caudal poles of the kidney where possible (maximum scan distance
28 mm). The slice thickness between scanning planes was 0.072 mm with a maximum of 500
slices. The images were captured in digital raw format (RF). Offline processing of 3D recon-
structions was performed using Vevo 2100 software (v1.6.0) on a dedicated workstation. The
resulting 3D model was used to determine the total kidney and cyst volumes and the number
of cysts.
Tissue sectioning, PAS staining, and cystic index determination
For histological examination, one of the kidneys from each rat was sliced perpendicularly to
the long axis at approximately 2 mm intervals. Slices from the midportion of the kidneys were
fixed in 10% buffered formalin overnight, and tissues were then embedded in paraffin.
Three μm sections were stained with periodic acid-Schiff (PAS) following a routine protocol.
The stained sections were subjected to cystic index analysis, using the HistoQuest image analy-
sis software (TissueGnostics, Vienna, Austria). The total kidney area (TKA) and the medullary
cystic area (MCA) were determined, and the cystic index was calculated in percent as MCA/
TKA100.
Immunohistochemical analysis
Immunohistochemistry for Ki67 was performed on 3 μm tissue sections which were deparaffi-
nized and rehydrated. Antigen retrieval was performed in an autoclave oven. Mouse anti-Ki67
antibody (BD Pharmingen, San Jose, CA, USA) was applied for 1 hour. Sections were washed
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and incubated with the biotinylated secondary antibody (Vector Laboratories Inc. Burlingame,
CA, USA) for 30 minutes. After washing, the ABC reagent (Vector) was applied to the sections
using 3,3’-diaminobenzidine with metal enhancement as the detection reagent. The percentage
of Ki-67 positive cells was determined from the total number of cells in cysts and non-cystic tu-
bules from each kidney section. We counted the total number of cells in 10 random fields con-
taining cysts and 10 random fields of non-cystic tissue in each kidney section of each PCK rat
using HistoQuest image analysis software (TissueGnostics, Vienna, Austria).
Determination of cAMP content of whole kidneys
The frozen kidneys were ground to fine powder under liquid nitrogen in a stainless steel mor-
tar. After the liquid nitrogen had evaporated, tissue was weighed and homogenized in 10 vol-
umes of 0.1 M HCl. After centrifugation at 600 g for 10 min at room temperature, the
supernatants were collected and assayed for cAMP without acetylation using an enzyme im-
munoassay kit (Sigma-Aldrich, Inc., St. Louis, MO, USA). The protein content was determined
by using the BCA protein assay kit from Pierce (Rockford, Illinois, USA). The results were ex-
pressed in pmol/mg of protein.
Statistics
Data are expressed as means ± SE. The individual parameters of the DAPA group were com-
pared with those of the CON group by a two-tailed Student’s t-test for unpaired data by using
the GraphPad Prism version 5.0 software (GraphPad, San Diego, CA, USA). P values of<0.05
were considered statistically significant.
Results
Effect of DAPA treatment on body weight, diuresis and electrolytes
Treatment with DAPA was well tolerated in PCK rats and they appeared healthy throughout
the 6 week treatment phase. Treatment of 6-week old male PCK rats with DAPA (10 mg/kg/d)
induced immediate and sustained glucosuria that was accompanied by a 2-fold increase in
water intake and a 3-fold increase in urine output when compared with vehicle-treated controls
(Table 1). Feces output was also increased by 23% at 3 week and by 45% at 6 week in DAPA-
treated PCK rats compared with controls. Plasma glucose (Pglucose) levels did not change in re-
sponse to DAPA, and plasma osmolality (Posm), sodium (PNa
+) and chloride (PCl
-) concentra-
tions remained stable at 3 and 6 weeks of treatment. DAPA-treated PCK rats displayed a
slightly enhanced urine sodium and chloride excretion rate compared with vehicle-treated rats.
Of note, DAPA-treated rats had a 6.4% lower body weight than controls at the end of the 6
week treatment phase (Table 1 and Fig 1A). Treatment with DAPA in normal SD rats also re-
sulted in the induction of glucosuria and an increase in water intake and urine output and a
slight increase in urine sodium and chloride, whereas PNa
+ and PCl
- remained stable (Table 2).
Effect of DAPA treatment on renal function and albuminuria
Table 3 shows that the plasma creatinine concentrations were similar at 3 weeks but tended to
increase at 6 weeks in DAPA-treated PCK rats. The plasma BUN concentrations were signifi-
cantly higher at 3 and 6 weeks of DAPA treatment. The clearances of creatinine and BUN were
significantly higher at 3 weeks, but the difference disappeared at 6 weeks of treatment with
DAPA. Calculating the [clearancecreatinine + clearanceBUN / 2] confirmed that there was a
higher clearance at 3 but not at 6 weeks of DAPA treatment in PCK rats (Fig 1B). Table 4
shows the data in normal SD rats. In DAPA-treated normal rats we did not see an increase in
Dapagliflozin and Polycystic Kidney Disease
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the creatinine and BUN clearances, and the [clearancecreatinine + clearanceBUN / 2] was also sim-
ilar between DAPA- vs. vehicle-treated SD rats. These data suggest that there was transient
hyperfiltration and subsequent deterioration of renal function upon treatment with DAPA in
PCK but not in SD rats.
Since albuminuria correlates with disease severity in PKD we analyzed the urine protein
content by SDS-PAGE and determined the urine albumin excretion by ELISA (Fig 2).
SDS-PAGE of urines (adjusted for 24 h urine volumes) revealed a marked increase of albumin-
uria in DAPA-treated PCK at 6 weeks (Fig 2A). The ELISA showed that albumin excretion
Table 1. Effect of DAPA on body weight, fluid balance and electrolytes in PCK rats.
Time point Baseline Day 21 Day 42
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 8 9 8
Age, week 6 6 9 9 12 12
Body weight, g 214 ± 5 210 ± 5 333 ± 5 324 ± 6 438 ± 6 410 ± 9*
Water intake, ml/d 31 ± 1 31 ± 1 48 ± 2 92 ± 2*** 40 ± 3 86 ± 8***
Diuresis, ml/d 10 ± 1 9 ± 1 18 ± 3 53 ± 2*** 19 ± 1 57 ± 7***
Posm, mosm/l 294.6 ± 2.2 293.8 ± 1.2 323.0 ± 2.4 315.4 ± 2.9 341.0 ± 7.5 351.6 ± 10.2
PNa
+, mmol/l 137.6 ± 1.6 139.5 ± 0.6 138.5 ± 0.4 140.8 ± 0.4 140.9 ± 0.7 138.8 ± 2.5
PCl
-, mmol/l 104.8 ± 0.8 105.5 ± 0.3 101.9 ± 0.5 103.9 ± 0.4 105.5 ± 1.6 104.0 ± 1.1
Pglucose, mmol/l 12.5 ± 1.4 10.6 ± 0.6 11.2 ± 0.4 11.3 ± 0.3 13.4 ±1.3 16.0 ± 2.7
Uosm, mosm/d 13.9 ± 0.7 14.2 ± 0.7 20.0 ± 2.1 57.2 ± 2.0*** 23.9 ±1.0 62.5 ± 5.6***
UNa
+, mmol/d 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.5 ± 0.2* 1.2 ± 0.1 1.8 ± 0.1***
UCl
-, mmol/d 2.0 ± 0.1 2.1 ±0.1 1.9 ±0.2 2.9 ± 0.2** 2.2 ± 0.1 3.3 ± 0.1***
Uglucose, mmol/d 0.1 ± 0.0 0.0 ± 0.0 0.3 ± 0.2 24.6 ± 0.9*** 0.3 ± 0.1 23.6 ± 4.3***
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliﬂozin.
*P<0.05
**P<0.01
***P<0.001, when comparing DAPA and CON at each time point. P, plasma; U, urine.
doi:10.1371/journal.pone.0125603.t001
Fig 1. Effect of DAPA on body weight and renal function.Course of body weight in vehicle (CON) and dapagliflozin (DAPA) treated PCK rats during the 6
week treatment phase (A). [Clearancecreatinine + ClearanceBUN / 2] at baseline (BL) and after 21 and 42 days of treatment in PCK rats (B). N = 8 per group.
Data are expressed as means ± SE.* P<0.05.
doi:10.1371/journal.pone.0125603.g001
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increased slightly at 3 weeks and a further increase was observed at 6 weeks in vehicle-treated
PCK rats, as expected (Fig 2B). In DAPA-treated rats the albuminuria increased markedly at 3
weeks and more importantly at 6 weeks. After 6 weeks the albumin excretion amounted to
1.7 ± 0.3 mg/d in vehicle-treated rats and to 6.8 ± 0.7 mg/day in DAPA-treated animals
(P<0.0001). In normal SD rats, the excretion of urine albumin was lower than in PCK rats but
also increased slightly upon treatment with DAPA for 5 weeks (0.4 ± 0.0 vs. 1.2 ± 0.2 mg/day,
P<0.05).
In vivo high resolution ultrasound imaging of rat kidneys
After 6 weeks of treatment, the PCK rats were anesthetized for ultrasound analysis of both kid-
neys. Fig 3A shows that the kidneys with the typical medullary cysts could be easily visualized
Table 2. Effect of DAPA on body weight, fluid balance and electrolytes in normal SD rats.
Time point Baseline Day 18 Day 35
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 9 9 8
Age, week 5 5 7.5 7.5 10 10
Body weight, g 144 ± 2 149 ± 7 285 ± 5 297 ± 7 349 ± 5 354 ± 6
Water intake, ml/d 32 ± 1 32 ± 3 41 ± 2 54 ± 2*** 49 ± 3 62 ± 7*
Diuresis, ml/d 11 ± 1 12 ± 1 17 ± 2 24 ± 3* 32 ± 2 36 ± 4
PNa
+, mmol/l 138.9 ± 0.4 142.3 ± 3.4 138.4 ± 0.4 133.5 ± 1.6* 141.9 ± 0.5 140.4 ± 0.6
PCl
-, mmol/l 100.9 ± 0.3 100.6 ± 1.0 100.3 ± 0.3 94.0 ± 3.0 100.9 ± 0.3 95.9 ± 2.3
Pglucose, mmol/l 10.5 ± 0.6 10.3 ± 0.2 9.9 ± 0.2 9.7 ± 0.3 13.4 ± 0.2 13.0 ± 0.5
UNa
+, mmol/d 1.3 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.4 ± 0.1 1.1 ± 0.3 1.6 ± 2.0
UCl
-, mmol/d 2.1 ± 0.1 1.8 ± 0.2 1.8 ± 0.1 2.1 ± 0.1 2.3 ± 0.1 2.4 ± 0.5
Uglucose, mmol/d 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 10.6 ± 0.6*** 0.0 ± 0.0 13.5 ± 2.0***
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliﬂozin.
*P<0.05
**P<0.01
***P<0.001, when comparing DAPA and CON at each time point. P, plasma; U, urine.
doi:10.1371/journal.pone.0125603.t002
Table 3. Effect of DAPA on renal function in PCK rats.
Time point Baseline Day 21 Day 42
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 8 9 8
Age, week 6 6 9 9 12 12
Pcreatinine, μmol/l 18.0 ± 0.0 18.0 ± 0.0 21.9 ±0.5 21.4 ±0.5 26.9 ± 1.2 36.1 ± 6.7
Clearancecreatinine, ml/min 2.4 ± 0.2 2.7 ± 0.2 2.6 ± 0.2 3.1 ±0.1* 3.2 ± 0.2 2.7 ± 0.3
PBUN, mmol/l 3.7 ± 0.1 3.9 ±0.1 4.1 ± 0.2 4.9 ± 0.2* 5.7 ± 0.1 7.1 ± 0.6*
ClearanceBUN, ml/min 1.0 ± 0.1 1.1 ± 0.1 1.2 ±0.1 1.7 ± 0.1** 1.3 ± 0.1 1.4 ± 0.1
[Clearancecreatinine + ClearanceBUN / 2] 1.7 ± 0.1 1.9 ± 0.1 1.8 ± 0.1 2.3 ± 0.1* 2.2 ± 0.1 2.0 ± 0.1
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliﬂozin.
*P<0.05
**P<0.01, when comparing CON and DAPA at each time point. P, plasma.
doi:10.1371/journal.pone.0125603.t003
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in vehicle-treated male PCK rats. On the other hand, DAPA-treated rats displayed larger kid-
neys and had substantially bigger cysts (Fig 3B). Ultrasound-based measurements revealed a
35% higher total kidney volume (P<0.01), a 2-fold higher cyst volume (P<0.05) and a 47%
higher cystic index (P<0.05) in DAPA- vs. vehicle-treated rats, whereas the number of cysts
was similar in both groups after 6 weeks of treatment (P = 0.841) (Fig 3C–3F).
Effect of DAPA treatment on kidney weight and morphology
After 6 weeks of treatment with DAPA the total weight of both kidneys was 23% higher in
DAPA- as compared with vehicle-treated male PCK rats (4.32 ± 0.24 vs. 5.33 ± 0.20 g,
P<0.01). The two kidneys to body weight (2K/BW) ratio was also significantly increased by
34% in the DAPA-treated rats (P<0.001). PAS-staining of kidney sections revealed that the
Table 4. Effect of DAPA on renal function in normal SD rats.
Time point Baseline Day 18 Day 35
Treatment group CON DAPA CON DAPA CON DAPA
Number of animals 9 9 9 9 9 8
Age, week 5 5 7.5 7.5 10 10
Pcreatinine, μmol/l 26.5 ± 0.0 26.5 ± 0.1 26.5 ± 0.0 26.5 ± 0.2 35.3 ± 2.5 35.3 ± 3.2
Clearancecreatinine, ml/min 1.7 ± 0.1 1.2 ± 0.3 2.0 ± 0.1 2.0 ± 0.2 2.6 ± 0.1 2.7 ± 0.2
PBUN, mmol/l 6.6 ± 0.3 5.5 ± 0.2 6.1 ± 0.2 8.2 ± 0.4*** 6.6 ± 0.1 9.9 ± 1.5*
ClearanceBUN, ml/min 0.6 ± 0.0 0.8 ± 0.1 0.8 ± 0.0 0.8 ± 0.1 1.1 ± 0.0 0.8 ± 0.2*
[Clearancecreatinine + ClearanceBUN / 2] 1.1 ± 0.1 1.0 ± 0.2 1.4 ± 0.1 1.2 ± 0.2 1.9 ± 0.1 1.9 ± 0.1
Data are expressed as means ± SE. CON, vehicle control; DAPA, dapagliﬂozin.
*P<0.05
**P<0.01
***P<0.001 when comparing CON and DAPA at each time point. P, plasma.
doi:10.1371/journal.pone.0125603.t004
Fig 2. Effect of DAPA on albumin excretion. Urine protein analysis by SDS-PAGE from urine samples of PCK rats after 6 weeks of treatment with vehicle
(CON) or dapagliflozin (DAPA). Each lane shows urine sample of a single PCK rat. Sample volumes were corrected for diuresis and amounted to 15 μl for
CON and 45 μl for DAPA. Arrow shows the band for albumin. M = molecular weight marker (A). Urine albumin concentration as measured by ELISA, in mg/
day (B). N = 8 per group. Columns represent means ± SE. **P<0.01, ***P<0.001 when comparing CON and DAPA at each time point, ns = non-significant.
doi:10.1371/journal.pone.0125603.g002
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cyst index was increased by 43% in DAPA-treated rats (P<0.05) while the total cyst number
was not significantly changed (P = 0.074) (Figs 4 and 5). In normal SD rats the total kidney
weight of both kidneys was also higher in DAPA-treated rats as compared to the total kidney
weight in vehicle-treated rats (3.1± 0.3 vs. 2.3 ± 0.2 g, P = 0.0002).
Fig 3. Effect of DAPA on kidney volume and cystic index. Typical 2D transverse power Doppler ultrasound images of a kidney in CON- and DAPA-
treated PCK rats. The red areas represent a power Doppler signal consistent with blood flow within the renal vasculature. The maximum scan distance
between cranial and caudal poles of the kidney was 28 mm. The slice thickness between scanning planes was 0.072 mmwith a maximum of 500 slices (A,
B). Change in kidney volume (C), cyst volume (D), cystic index (E) and number of cysts (F) in PCK rats. N = 6 rats or 12 kidneys per group. Columns
represent means ± SE. *P<0.05, **P<0.01, ns = non-significant.
doi:10.1371/journal.pone.0125603.g003
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Effect of DAPA treatment on renal cAMP content and renal epithelial cell
proliferation
Since cAMP is a major driver of cyst growth we analyzed the content of cAMP in PCK kidney
tissue by ELISA. Fig 6 shows that the amount of cAMP per mg of total protein was similar in
DAPA- and vehicle-treated male PCK rats (P = 0.717).
Immunohistochemistry staining for Ki67 was then used to examine whether DAPA treat-
ment had an effect on tubular and cystic epithelial cell proliferation. Fig 7 shows no significant
change in the number of Ki67-positive nuclei in the cystic epithelium in DAPA-treated PCK
rats. Quantification of the Ki67-positive nuclei confirmed that the number of Ki67-positive nu-
clei was not changed in cystic epithelium as well as in non-cystic epithelium in DAPA- vs. vehi-
cle-treated PCK rats (Table 5).
Discussion
Here we show that the induction of osmotic diuresis with the SGLT2-specific inhibitor DAPA
leads to an unexpected increase in the kidney and renal cyst volumes of PCK rats, an ortholo-
gous model of ARPKD. Furthermore, DAPA-treated PCK but not normal SD rats displayed a
transient increase in the clearances of creatinine and BUN and a progressive increase in albu-
minuria which suggests that DAPA promotes hyperfiltration in PCK rats. The renal cAMP
Fig 4. Effect of DAPA on kidney weight and cyst index.Ratio of two kidney weights to total body weight (2KW/TBW) (A), cyst index (B) and number of
cysts (C) after 6 week treatment with vehicle (CON) or DAPA in PCK rats. N = 8 per group. Columns represent means ± SE. *P<0.05, ***P<0.001, ns = non-
significant.
doi:10.1371/journal.pone.0125603.g004
Dapagliflozin and Polycystic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0125603 April 30, 2015 9 / 14
Fig 5. Effect of DAPA on renal histology.Representative renal histology by periodic acid-Schiff (PAS) staining of kidneys in vehicle- treated (CON) PCK
(A,E) and normal SD (C,G) rats and in DAPA-treated PCK (B,F) and normal SD (D,H) rats. Scale bar is 2000 μm in A and B and 500 μm in C and D.
doi:10.1371/journal.pone.0125603.g005
Fig 6. Effect of DAPA on renal cAMP content. Analysis of cAMP concentration per mg protein in PCK rat kidneys treated with vehicle (CON) or
dapagliflozin (DAPA). N = 8 per group. Columns represent means ± SE. ns = non-significant.
doi:10.1371/journal.pone.0125603.g006
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content was similar, and there was no evidence for heightened epithelial cell proliferation
which could explain the greater cyst volume upon treatment with DAPA. Thus, the induction
of glucosuria with DAPA appeared to have a negative impact on cystic disease progression in
PCK rats.
The increase in glomerular filtration in response to DAPA appeared to be transient, i.e. it
was seen after 3 weeks but not after 6 weeks. However it was associated with an increase in al-
buminuria at 3 weeks and a further increase at 6 weeks. In general, an increase in albuminuria
is seen with progressing stages of PKD [20]. The increased amount of urine albumin could be
Fig 7. Effect of DAPA on cell proliferation. Representative areas of Ki67 immunohistochemical staining in PCK rat kidneys are shown. Nuclei of
Ki67-positive cells were stained brown with 3,3’-diaminobenzidine and that of Ki67-negative cells appeared blue because of the counterstaining with
hematoxylin. CON (cystic area) (A), DAPA (cystic area) (B), CON (non-cystic area) (C), DAPA (non-cystic area) (D). Scale bar is 200 μm in A, B, C and D.
doi:10.1371/journal.pone.0125603.g007
Table 5. Effect of DAPA on cell proliferation in PCK rat kidneys.
Treatment CON DAPA Difference, % P-value
Number of animals 7 7
Ki67-positive cells (%) in cyst-lining epithelium 6.5 ± 1.3 6.7 ± 1.9 + 3.5 0.922
Ki67-positive cells (%) in non-cystic tubules 2.5 ± 0.91 3.1 ± 1.1 + 24.7 0.677
Morphometric analysis using Ki67, a proliferation marker in kidney medulla of vehicle (CON)- and DAPA-treated PCK rats. Data are expressed as
means ± SE.
doi:10.1371/journal.pone.0125603.t005
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the consequence of enhanced leakage of albumin from glomeruli, or alternatively it could be
caused by decreased tubular reabsorption. Whether albuminuria is reflecting glomerular
hyperfiltration damage needs to be examined further.
Treatment with SGLT2 inhibitors has been associated with a decrease in the GFR in normal
and diabetic rats and in humans with type 2 diabetes mellitus [21,22]. This contrasts with our
findings in PCK rats which display evidence of transient hyperfiltration. This hyperfiltration
could in part be explained by the enhanced food i.e. protein intake which is seen in response to
DAPA [23], since protein loading is a known stimulus for increasing glomerular filtration.
However this should have been counterbalanced by the higher sodium delivery at the macula
densa which normally leads to afferent arteriolar vasoconstriction [24]. Since normal rats
which are treated with DAPA do not develop hyperfiltration and albuminuria [25–27], the ef-
fects that we observed appear to be specific to the PCK model of PKD.
In a previous study, we found that treatment with the SGLT1/SGLT2 inhibitor phlorizin at-
tenuated albuminuria in Han:SPRD rats, improved GFR, and decreased cyst growth [18]. Con-
trasting with these results, the DAPA-treated PCK rats displayed enhanced cyst growth. Han:
SPRD rats are a non-orthologous model of PKD, with cyst formation exclusively in the proxi-
mal tubules [28,29]. In contrast, PCK rats display cyst formation in the distal nephron. Typical-
ly, the cysts disconnect from the original proximal tubule in Han:SPRD, whereas in PCK rats
the cysts remain connected to the distal tubule. We speculate that the increased intratubular os-
motic pressure which is caused by the glucosuria could promote the dilation of distal tubular
segments and cysts. This could cause compression of adjacent healthy distal tubules and pro-
vide a stimulus to enhance GFR, as it may be seen in partial obstructive uropathy [30].
The enhanced cyst growth did not appear to be the consequence of vasopressin-mediated
cAMP stimulation, since the renal cAMP content was similar between DAPA- and vehicle-
treated PCK rats. Despite a massive increase in the diuresis, DAPA-treated rats did not appear
to be dehydrated, and the serum sodium concentrations did not increase. This suggests indi-
rectly that vasopressin levels did not increase. Furthermore, Ki67 staining did not reveal an in-
crease in proliferating cells in dilated tubules, and there was no change in the number of nuclei
in the cysts upon DAPA treatment. This indicates again that the cysts increased in size due to
osmotic pressure without affecting epithelial cell proliferation.
Diabetes may occur in patients with ADPKD and it is associated with greater cardiovascular
morbidity [31]. With the possibility to treat ADPKD patients with SGLT2 inhibitors there
could be a risk of albuminuria and increased cyst growth. Although such a complication has
not yet been described caution should be exerted when prescribing these drugs to patients with
ADPKD.
In summary, we have shown that the induction of osmotic diuresis by inhibiting SGLT2
promotes transient hyperfiltration, albuminuria and increased cyst volume in PCK rats. Fur-
ther studies need to explore the mechanisms which link the enhanced glomerular filtration to
the increase in cyst volume upon SGLT inhibition in this model of PKD.
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